Author

Rustem Airatovich Gafanov

Observed names: Gafanov Rustem, Gafanov, Rustem, Gafanov, Rustem Airatovich, R A Gafanov, R. A. Gafanov, R. Airatovich Gafanov, R. Gafanov, R.A. Gafanov, R. A. Gafanov, Rustem A. Gafanov, Rustem Gafanov, Гафанов Р. А., Гафанов Рустем Айратович, Р. А. Гафанов, Р.А. Гафанов, Рустем Айратович Гафанов

Institution: Federal State Budgetary Institution Russian Scientific Center of Roentgenoradiology

Observed institutions: Fox Chase Cancer Center, Cleveland Clinic, Ivano-Frankivsk National Medical University, Sumy State University, Federal State Budgetary Institution Russian Scientific Center of Roentgenoradiology, Ministry of Health of the Russian Federation, Dnipro State Medical University

ORCID: 0000-0002-7592-0392

Observed ORCID: 0000-0002-7592-0392

OpenAlex ID: A5036414302

Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

2019 · Brian I. Rini, Elizabeth R. Plimack, et al. · New England Journal of Medicine · 3,543

PDF

Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial

2020 · Thomas Powles, Elizabeth R Plimack, et al. · The Lancet Oncology · 776

Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial

2021 · Thomas Powles, Tibor Csőszi, et al. · The Lancet Oncology · 663

Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial

2021 · Christopher Sweeney, Sergio Bracarda, et al. · The Lancet · 357

Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

2022 · Thomas Powles, Piotr Tomczak, et al. · The Lancet Oncology · 320

PDF

Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non–Clear Cell Renal Cell Carcinoma

2021 · David F. McDermott, Jae-Lyun Lee, et al. · Journal of Clinical Oncology · 304

PDF

Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial

2022 · Smith, Matthew, R., Scher, Howard, et al. · Research at the University of Copenhagen (University of Copenhagen) · 217

Darolutamide in Combination With Androgen-Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer From the Phase III ARANOTE Trial

2024 · Fred Saad, Egils Vjaters, et al. · Journal of Clinical Oncology · 199

Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial

2022 · Matthew R Smith, Howard I Scher, et al. · The Lancet Oncology · 189

PDF

Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study

2023 · Elizabeth R. Plimack, Thomas Powles, et al. · European Urology · 172

Pembrolizumab Plus Olaparib for Patients With Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: The Randomized, Open-Label, Phase III KEYLYNK-010 Trial

2023 · Emmanuel S. Antonarakis, Se Hoon Park, et al. · Journal of Clinical Oncology · 161

PDF

Open-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell Carcinoma

2021 · David F. McDermott, Jae-Lyun Lee, et al. · Journal of Clinical Oncology · 138

PDF

Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for metastatic renal cell carcinoma (mRCC): Outcomes in the combined IMDC intermediate/poor risk and sarcomatoid subgroups of the phase 3 KEYNOTE-426 study.

2019 · Brian I. Rini, Elizabeth R. Plimack, et al. · Journal of Clinical Oncology · 123

Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Results from 42-month follow-up of KEYNOTE-426.

2021 · Brian I. Rini, Elizabeth R. Plimack, et al. · Journal of Clinical Oncology · 108

Pembrolizumab monotherapy as first-line therapy in advanced clear cell renal cell carcinoma (accRCC): Results from cohort A of KEYNOTE-427.

2018 · David F. McDermott, Jae-Lyun Lee, et al. · Journal of Clinical Oncology · 91

Pembrolizumab plus axitinib versus sunitinib for advanced clear cell renal cell carcinoma: 5-year survival and biomarker analyses of the phase 3 KEYNOTE-426 trial

2025 · Brian I. Rini, Elizabeth R. Plimack, et al. · Nature Medicine · 87

PDF

Pembrolizumab Plus Docetaxel Versus Docetaxel for Previously Treated Metastatic Castration-Resistant Prostate Cancer: The Randomized, Double-Blind, Phase III KEYNOTE-921 Trial

2025 · Daniel P. Petrylak, Raffaele Ratta, et al. · Journal of Clinical Oncology · 79

PDF

Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma: 5-year analysis of KEYNOTE-426.

2023 · Brian I. Rini, Elizabeth R. Plimack, et al. · Journal of Clinical Oncology · 79

Capivasertib plus abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer: CAPItello-281 phase III study

2025 · K. Fizazi, N.W. Clarke, et al. · Annals of Oncology · 71

PDF

Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced renal cell carcinoma (RCC): Updated analysis of KEYNOTE-426.

2020 · Elizabeth R. Plimack, Brian I. Rini, et al. · Journal of Clinical Oncology · 65

First-line pembrolizumab (pembro) monotherapy for advanced non-clear cell renal cell carcinoma (nccRCC): Results from KEYNOTE-427 cohort B.

2019 · David F. McDermott, Jae-Lyun Lee, et al. · Journal of Clinical Oncology · 53

KEYNOTE-921: Phase III Study of Pembrolizumab Plus Docetaxel for Metastatic Castration-Resistant Prostate Cancer

2021 · Daniel P Petrylak, Raffaele Ratta, et al. · Future Oncology · 49

Phase 3 KEYNOTE-361 trial: Pembrolizumab (pembro) with or without chemotherapy versus chemotherapy alone in advanced urothelial cancer.

2017 · Thomas Powles, Juergen E. Gschwend, et al. · Journal of Clinical Oncology · 48

2022 · Jens Bedke, Brian I. Rini, et al. · European Urology · 42

LBA4 IPATential150: Phase III study of ipatasertib (ipat) plus abiraterone (abi) vs placebo (pbo) plus abi in metastatic castration-resistant prostate cancer (mCRPC)

2020 · J.S. de Bono, S. Bracarda, et al. · Annals of Oncology · 37

Works count: 112

Citation count: 8,300

H-index: 27

I10-index: 38